Mineralys Therapeutics Inc (MLYS)

$27.35 +0.36 (1.33%)
Market Cap 2.26B
Revenue (ttm) 0.00
Net Income (ttm) -154.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 386,100
Avg Vol 1,451,826
Day's Range N/A - N/A
Shares Out 82.50M
Stochastic %K 82%
Beta 0.68
Analysts Strong Sell
Price Target $49.00

Company Profile

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name t...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 378 6240
Address:
150 N. Radnor Chester Road, Suite F200, Radnor, United States
CH_Expat
CH_Expat Aug. 7 at 6:34 PM
$XBI outperformed $MLYS S by 52% YTD Yes, the same XBI that is mainly consisting of shitcos.
0 · Reply
CH_Expat
CH_Expat Aug. 6 at 4:26 PM
$MLYS Valuations in bioland are nuts. I still see value here. Hard to imagine this goes down to low 20s again with the PDUFA four months ahead. I still hate averaging up as a sector correction is overdue. Damn it. Maybe I should just buy AI shit instead of the bio mindfuck.
1 · Reply
RandomInvestor777
RandomInvestor777 Aug. 1 at 12:19 AM
$MLYS 2b-2.5B peak sales for rHTN CKD will add another 2b-3b peak. both conservative peak revenues This should sell soon and should not be any less than 5B. Ideally 6B+
0 · Reply
CH_Expat
CH_Expat Jul. 31 at 1:26 PM
$MLYS A cool random 2,6m buy AH. But hey, all normal. @masonat
0 · Reply
CH_Expat
CH_Expat Jul. 30 at 3:46 PM
$MLYS Hunger games to make us bail.
0 · Reply
CH_Expat
CH_Expat Jul. 24 at 8:59 AM
$MLYS Playbook for me is clear: I will not hold through PUFDA. It will be approved, so there will be either a selloff or a flat reaction. They will not make it alone against AZN/CinCor. We will see if it works out by then with the BO. More than enough candidates.
1 · Reply
Diiiii
Diiiii Jul. 23 at 12:06 PM
$MLYS (Common Misconceptions) ・Hypertension is a mundane condition and not a major issue. ・As a "second-to-market" player following AZN's approval, there is no room to make an impact. ・The decline in the stock price from last year's highs reflects these factors. (Matters likely to become clear in the near future) ・The market size for the ASI category is significantly larger than bears anticipate. ・Although Lorundrostat would be the second drug approved in the class, it holds the potential to be "best-in-class." ・The regulatory review encompasses data on CKD in addition to hypertension (HTN), with HFpEF also within scope for future indications. ・For Big Pharma, an acquisition could serve as a "kill two birds with one stone" move: addressing the patent cliff while preventing AstraZeneca (AZN) from monopolizing the class.
1 · Reply
CH_Expat
CH_Expat Jul. 23 at 11:08 AM
$IDYA Adding zone 28-30. $MLYS Adding zone 23-24 Candidates at lower prices: CLDX, TRVI, NRIX, IVA, SNDX, KURA Candidates at much lower prices: COGT, CELC Horror-All-Star-Trash-Team: ALT, SLS, TNXP, CADL, CAPR
4 · Reply
RandomInvestor777
RandomInvestor777 Jul. 21 at 6:35 PM
$MLYS if the stock isn't before PDUFA, It will tank They cannot compete against AZN, everyone knows that even the mgmt said so explicitly. And they need money to fund trials for other indications so it will tank hard unless bought before which is why they're looking to sell the company, and its the smart thing to do
1 · Reply
CH_Expat
CH_Expat Jul. 21 at 2:36 PM
$MLYS I would not buy this stock for a pump after the likely approval. In fact I think there will be selloff - if the company is still independent by then. Matter of price. Sure they could sell for 4b today, obviously not enough for Congleton. We will see.
0 · Reply
Latest News on MLYS
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Jul 27, 2026, 4:01 PM EDT - 13 days ago

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics presents late-breaking data on lorundrostat

2026-06-14T20:50:05.000Z - 2 months ago

Mineralys Therapeutics presents late-breaking data on lorundrostat

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Jun 14, 2026, 10:00 AM EDT - 2 months ago

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 2:40 PM EDT - 2 months ago

Mineralys Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 8, 2026, 4:05 PM EDT - 2 months ago

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Jun 8, 2026, 7:00 AM EDT - 2 months ago

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics falls -17.1%

2026-06-03T16:06:46.000Z - 2 months ago

Mineralys Therapeutics falls -17.1%

Mineralys Therapeutics falls -12.7%

2026-06-03T15:57:06.000Z - 2 months ago

Mineralys Therapeutics falls -12.7%

Mineralys prices offering of 5.66M shares of common stock at $26.50

2026-06-03T15:48:11.000Z - 2 months ago

Mineralys prices offering of 5.66M shares of common stock at $26.50

Mineralys Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 7:35 AM EDT - 2 months ago

Mineralys Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Mineralys to repurchase future royalty payments in Tanabe license agreement

2026-06-03T10:19:53.000Z - 2 months ago

Mineralys to repurchase future royalty payments in Tanabe license agreement

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Jun 3, 2026, 6:05 AM EDT - 2 months ago

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

Jun 3, 2026, 6:00 AM EDT - 2 months ago

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

Mineralys Therapeutics presents new data for lorundrostat

2026-05-31T21:05:04.000Z - 2 months ago

Mineralys Therapeutics presents new data for lorundrostat

Mineralys' pill cuts blood pressure in kidney disease patients

May 30, 2026, 11:20 AM EDT - 2 months ago

Mineralys' pill cuts blood pressure in kidney disease patients

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

May 30, 2026, 11:15 AM EDT - 2 months ago

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 27, 2026, 8:00 AM EDT - 2 months ago

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

Mineralys Therapeutics Transcript: AGM 2026

May 21, 2026, 3:30 PM EDT - 2 months ago

Mineralys Therapeutics Transcript: AGM 2026

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

May 18, 2026, 4:05 PM EDT - 2 months ago

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Mineralys Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 12:20 PM EDT - 3 months ago

Mineralys Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs

2026-05-07T19:15:38.000Z - 3 months ago

Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs

Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)

2026-05-07T00:50:30.000Z - 3 months ago

Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)

Mineralys Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Mineralys Therapeutics Earnings Call Transcript: Q1 2026

Mineralys Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Mineralys Therapeutics Earnings release: Q1 2026

Mineralys Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Mineralys Therapeutics Quarterly report: Q1 2026

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026, 4:05 PM EDT - 3 months ago

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics Slides: Corporate presentation

May 6, 2026, 4:00 PM EDT - 3 months ago

Mineralys Therapeutics Slides: Corporate presentation

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

May 5, 2026, 8:00 AM EDT - 3 months ago

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

Apr 29, 2026, 4:05 PM EDT - 3 months ago

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

Mineralys Therapeutics initiated with a Buy at TD Cowen

2026-04-27T09:40:39.000Z - 3 months ago

Mineralys Therapeutics initiated with a Buy at TD Cowen

Mineralys Therapeutics Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 4 months ago

Mineralys Therapeutics Proxy statement: Proxy filing

Mineralys Therapeutics Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 4 months ago

Mineralys Therapeutics Proxy statement: Proxy filing

Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board

2026-03-31T11:08:33.000Z - 4 months ago

Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board

IMUX

Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer

2026-03-24T12:11:17.000Z - 4 months ago

Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer

Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

Mineralys Therapeutics Slides: Corporate presentation

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Mineralys Therapeutics Slides: Corporate presentation

Mineralys Therapeutics price target raised to $51 from $46 at BofA

2026-03-13T12:12:20.000Z - 5 months ago

Mineralys Therapeutics price target raised to $51 from $46 at BofA

Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)

2026-03-12T20:36:58.000Z - 5 months ago

Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)

Mineralys Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 5 months ago

Mineralys Therapeutics Earnings Call Transcript: Q4 2025

Mineralys Therapeutics Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 5 months ago

Mineralys Therapeutics Annual report: Q4 2025

Mineralys Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 5 months ago

Mineralys Therapeutics Earnings release: Q4 2025

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 4:05 PM EDT - 5 months ago

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA

2026-03-09T20:35:52.000Z - 5 months ago

Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

Mar 9, 2026, 4:30 PM EDT - 5 months ago

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

Jan 6, 2026, 8:00 AM EST - 7 months ago

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

Dec 12, 2025, 11:00 AM EST - 8 months ago

Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

Mineralys Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:25 PM EST - 8 months ago

Mineralys Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Nov 26, 2025, 4:05 PM EST - 9 months ago

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 2:00 PM EST - 9 months ago

Mineralys Therapeutics Transcript: Stifel 2025 Healthcare Conference

Mineralys Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 9:30 AM EST - 9 months ago

Mineralys Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Mineralys Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 9 months ago

Mineralys Therapeutics Earnings Call Transcript: Q3 2025

Mineralys Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 9 months ago

Mineralys Therapeutics Quarterly report: Q3 2025

Mineralys Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 9 months ago

Mineralys Therapeutics Earnings release: Q3 2025

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 4:05 PM EST - 9 months ago

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 9 months ago

Mineralys Therapeutics Slides: Corporate Presentation

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

Nov 7, 2025, 6:10 PM EST - 9 months ago

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025

Oct 21, 2025, 8:00 AM EDT - 10 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025

Mineralys Therapeutics Slides: Corporate Presentation

Oct 1, 2025, 7:00 AM EDT - 11 months ago

Mineralys Therapeutics Slides: Corporate Presentation

Mineralys Therapeutics Transcript: Stifel Virtual Cardiometabolic Forum

Sep 30, 2025, 1:30 PM EDT - 11 months ago

Mineralys Therapeutics Transcript: Stifel Virtual Cardiometabolic Forum

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

Sep 30, 2025, 8:00 AM EDT - 11 months ago

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Sep 5, 2025, 9:00 AM EDT - 1 year ago

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 4, 2025, 4:01 PM EDT - 1 year ago

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Mineralys Therapeutics Slides: Corporate Presentation

Sep 4, 2025, 2:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: Corporate Presentation

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Sep 2, 2025, 9:33 PM EDT - 1 year ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Sep 2, 2025, 4:01 PM EDT - 1 year ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mineralys Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q2 2025

Mineralys Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Quarterly report: Q2 2025

Mineralys Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Earnings release: Q2 2025

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Aug 4, 2025, 4:05 PM EDT - 1 year ago

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Jun 30, 2025, 11:17 AM EDT - 1 year ago

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Mineralys Therapeutics Transcript: Study Result

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: Study Result

Mineralys Therapeutics Press release: Study Result

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Press release: Study Result

Mineralys Therapeutics Slides: Study Result

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: Study Result

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

Mineralys Therapeutics Slides: FY 2025

May 25, 2025, 11:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: FY 2025

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

May 24, 2025, 4:30 AM EDT - 1 year ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

May 20, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

Mineralys Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 7:35 PM EDT - 1 year ago

Mineralys Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

Mineralys Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q1 2025

Mineralys Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Quarterly report: Q1 2025

Mineralys Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Earnings release: Q1 2025

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 4:05 PM EDT - 1 year ago

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

May 5, 2025, 4:05 PM EDT - 1 year ago

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Apr 23, 2025, 5:23 PM EDT - 1 year ago

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Mineralys Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Proxy statement: Proxy Filing

Mineralys Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Proxy statement: Proxy Filing

Mineralys Therapeutics Transcript: KOL Event

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: KOL Event

Mineralys Therapeutics Slides: KOL Event

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: KOL Event

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mar 29, 2025, 2:30 PM EDT - 1 year ago

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mar 18, 2025, 4:01 PM EDT - 1 year ago

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mar 11, 2025, 10:20 PM EDT - 1 year ago

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Transcript: Study Result

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: Study Result

Mineralys Therapeutics Press release: Study Result

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Press release: Study Result

Mineralys Therapeutics Slides: Study Result

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: Study Result

Mineralys Therapeutics' blood pressure drug meets goal in trials

Mar 10, 2025, 7:12 AM EDT - 1 year ago

Mineralys Therapeutics' blood pressure drug meets goal in trials

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mar 10, 2025, 7:00 AM EDT - 1 year ago

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Mar 7, 2025, 4:01 PM EST - 1 year ago

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Mineralys Therapeutics Earnings Call Transcript: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q4 2024

Mineralys Therapeutics Annual report: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Mineralys Therapeutics Annual report: Q4 2024

Mineralys Therapeutics Earnings release: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Mineralys Therapeutics Earnings release: Q4 2024

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 12, 2025, 7:00 AM EST - 1 year ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Feb 5, 2025, 4:05 PM EST - 1 year ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Mineralys Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 4, 2024, 4:15 PM EST - 1 year ago

Mineralys Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Mineralys Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 10:20 AM EST - 1 year ago

Mineralys Therapeutics Transcript: Stifel 2024 Healthcare Conference

Mineralys Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 4:00 PM EST - 1 year ago

Mineralys Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Mineralys Therapeutics Earnings Call Transcript: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q3 2024

Mineralys Therapeutics Quarterly report: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Mineralys Therapeutics Quarterly report: Q3 2024

Mineralys Therapeutics Earnings release: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Mineralys Therapeutics Earnings release: Q3 2024

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 11, 2024, 4:05 PM EST - 1 year ago

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Nov 5, 2024, 4:05 PM EST - 1 year ago

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

CH_Expat
CH_Expat Aug. 7 at 6:34 PM
$XBI outperformed $MLYS S by 52% YTD Yes, the same XBI that is mainly consisting of shitcos.
0 · Reply
CH_Expat
CH_Expat Aug. 6 at 4:26 PM
$MLYS Valuations in bioland are nuts. I still see value here. Hard to imagine this goes down to low 20s again with the PDUFA four months ahead. I still hate averaging up as a sector correction is overdue. Damn it. Maybe I should just buy AI shit instead of the bio mindfuck.
1 · Reply
RandomInvestor777
RandomInvestor777 Aug. 1 at 12:19 AM
$MLYS 2b-2.5B peak sales for rHTN CKD will add another 2b-3b peak. both conservative peak revenues This should sell soon and should not be any less than 5B. Ideally 6B+
0 · Reply
CH_Expat
CH_Expat Jul. 31 at 1:26 PM
$MLYS A cool random 2,6m buy AH. But hey, all normal. @masonat
0 · Reply
CH_Expat
CH_Expat Jul. 30 at 3:46 PM
$MLYS Hunger games to make us bail.
0 · Reply
CH_Expat
CH_Expat Jul. 24 at 8:59 AM
$MLYS Playbook for me is clear: I will not hold through PUFDA. It will be approved, so there will be either a selloff or a flat reaction. They will not make it alone against AZN/CinCor. We will see if it works out by then with the BO. More than enough candidates.
1 · Reply
Diiiii
Diiiii Jul. 23 at 12:06 PM
$MLYS (Common Misconceptions) ・Hypertension is a mundane condition and not a major issue. ・As a "second-to-market" player following AZN's approval, there is no room to make an impact. ・The decline in the stock price from last year's highs reflects these factors. (Matters likely to become clear in the near future) ・The market size for the ASI category is significantly larger than bears anticipate. ・Although Lorundrostat would be the second drug approved in the class, it holds the potential to be "best-in-class." ・The regulatory review encompasses data on CKD in addition to hypertension (HTN), with HFpEF also within scope for future indications. ・For Big Pharma, an acquisition could serve as a "kill two birds with one stone" move: addressing the patent cliff while preventing AstraZeneca (AZN) from monopolizing the class.
1 · Reply
CH_Expat
CH_Expat Jul. 23 at 11:08 AM
$IDYA Adding zone 28-30. $MLYS Adding zone 23-24 Candidates at lower prices: CLDX, TRVI, NRIX, IVA, SNDX, KURA Candidates at much lower prices: COGT, CELC Horror-All-Star-Trash-Team: ALT, SLS, TNXP, CADL, CAPR
4 · Reply
RandomInvestor777
RandomInvestor777 Jul. 21 at 6:35 PM
$MLYS if the stock isn't before PDUFA, It will tank They cannot compete against AZN, everyone knows that even the mgmt said so explicitly. And they need money to fund trials for other indications so it will tank hard unless bought before which is why they're looking to sell the company, and its the smart thing to do
1 · Reply
CH_Expat
CH_Expat Jul. 21 at 2:36 PM
$MLYS I would not buy this stock for a pump after the likely approval. In fact I think there will be selloff - if the company is still independent by then. Matter of price. Sure they could sell for 4b today, obviously not enough for Congleton. We will see.
0 · Reply
SV777
SV777 Jul. 20 at 9:21 PM
$MLYS the fact that its holding at 26 is insane 50-55 buyout?
1 · Reply
CH_Expat
CH_Expat Jul. 17 at 9:46 AM
$MLYS Beat it down to double down.
0 · Reply
Bondra
Bondra Jul. 14 at 6:32 PM
$MLYS I know good company when i see it. 3000 share starter
2 · Reply
Diiiii
Diiiii Jul. 13 at 12:45 PM
$MLYS The $MLYS Bull Thesis: Two Independent Paths to Upside https://claude.ai/public/artifacts/287c85f8-512a-48c3-bb00-3b087da5c7eb
0 · Reply
CH_Expat
CH_Expat Jul. 9 at 3:56 PM
$MLYS Gimme low 20s one last time.
3 · Reply
SV777
SV777 Jul. 8 at 2:23 PM
$MLYS sell the company for 8-10b
1 · Reply
BioStick123
BioStick123 Jul. 7 at 5:20 PM
$MLYS relatively high buyout odds here...
0 · Reply
CH_Expat
CH_Expat Jul. 7 at 2:47 PM
$MLYS Keep in mind the Novo Nordisk Guy talked about bolt on acquisitions. Maybe they also bid for CRNX - and Vertex won. They need something and so does Novartis. Mr.Congleton has already two new board seats. Who has the balls to pay him what he wants before PUFDA?!
0 · Reply
Voxxx
Voxxx Jul. 7 at 1:55 PM
$MLYS
0 · Reply
BiodegradableBurger
BiodegradableBurger Jul. 7 at 1:40 PM
$MLYS Morning wood is always the greatest feeling.
0 · Reply
CH_Expat
CH_Expat Jul. 6 at 6:28 PM
$MLYS Luck returned to my side of the court.
1 · Reply
CH_Expat
CH_Expat Jul. 6 at 1:44 PM
$MLYS Added. Cash position was too high and most other quality bios are already bubbly.
0 · Reply